

Europäisches Patentamt **European Patent Office** Office eur péen des brev ts



(1) Publication number:

0 359 399 B1

#### **EUROPEAN PATENT SPECIFICATION** (P)

- (3) Date of publication of patent specification: 16.03.94 (5) Int. CI.5: C12P 21/02, C07K 1/00
- 21) Application number: 89308232.1
- ② Date of filing: 14.08.89
- Process for the enzymatic production of dipeptides.
- Priority: 12.08.88 DK 4521/88
- Date of publication of application: 21.03.90 Bulletin 90/12
- 45 Publication of the grant of the patent: 16.03.94 Bulletin 94/11
- (84) Designated Contracting States: AT BE CH DE ES FR GB GR IT LI LU NL SE
- 66) References cited:

EP-A- 0 074 095 EP-A- 0 017 485 EP-A- 0 154 472

EP-A- 0 220 923

EP-A- 0 269 390 EP-A- 0 278 787 Tomsgaardsvej 102

73 Proprietor: CARLBIOTECH LTD. A/S Tagensvej 16 DK-2200 Copenhagen N(DK)

inventor: Aasmul-Olsen, Stig Skodsborgvej 410, st.tv. DK-2942 Skodsborg(DK) Inventor: Thorbek, Pia Sdr. Jagtvel 39 DK-2970 Horsholm(DK) Inventor: Widmer, Fred

c/o Carlsberg Biotechnology Ltd. A/S

Tagensvej 16

DK-2200 Copenhagen N(DK) Inventor: Hansen, Soren

DK-2400 Copenhagen NV(DK)

Representative: Christiansen, Ejvind et al **HOFMAN-BANG & BOUTARD A/S** Adelgade 15 DK-1304 Copenhagen K (DK)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

### Description

The present invention concerns a process for enzymatic production of dipeptides and derivatives of dipeptides and having the general formula

H-A-B-Y

wherein A represents an optionally side-chain protected L-or D- $\alpha$ -amino acid residue or  $\omega$ -amino acid residue and B represents an optionally side-chain protected L- or D- $\alpha$ -aminocarboxylic acid residue which may be the same as or different from A, and L- or D-aminophosphonic acid residue or L- or D-aminosulfonic acid residue or the corresponding  $\omega$ -amino acids or salts and hydrates thereof, and Y is OH, H, alkyl, aryl, aralkyl or a C-terminal blocking group, with the proviso that A can not be Asp or Glu when B is Phe and Y is alkyl or BY represents an amino alcohol residue

B'-CHY'-OH

35

wherein B¹ is a decarboxy derivative of the aminocarboxylic acids as defined with relation to B, and Y¹ is H, alkyl, aryl or aralkyl.

In recent years there has been an increasing interest in dipeptides and dipeptide derivatives optionally containing an amino acid residue of D-configuration, with a view to their potential pharmacological effects, such as e.g. antibiotics. Likewise, there has been a great interest in dipeptides within fields such as artificial nutrition - human as well as veterinary -sweeteners and within agrochemistry, such as e.g. herbicides.

Such dipeptides H-A-B-Y can be produced by means of known chemical coupling reactions, but all these methods share the feature that, generally, it is necessary to protect the amino acids involved - A and B - on the amino group and the carboxylic acid group, respectively, and frequently also on the side chains if these carry functional groups. Further, there is an inherent risk of side reactions during the chemical coupling step because of the reagents and conditions employed, a major side reaction being recemization, particularly of the A-component. By replacing the chemical coupling step with an enzymatic coupling step proceeding under mild conditions, such side reactions and racemization can be avoided, yielding a stereochemically pure product.

The presence of amino- and carboxyl protective groups is mandatory in chemical coupling and has generally been regarded as mandatory also in prior art enzymatic coupling using endoproteases.

This adds several undesired features to these processes seriously afflicting their process economy on an industrial scale, particularly apparent in dipeptide synthesis.

The disadvantages are concerned with the introduction of these groups, as well as their removal and presence during process operation, increasing overall process cost and time and affecting overall yield.

Typical examples of amino protective groups commonly used are those of the carbobenzoxy (Z-) and tert-butoxycarbonyl (Boc-) type, which are of a molecular weight comparable to those of the amino acid residues. Firstly, the protective groups will have to be introduced in the starting materials by means of appropriate costly agents in a separate reaction step followed by an isolation step. While present, these hydrophobic groups often have a drastical effect upon the solubility of the intermediates and reaction products, and may afflict both the nature and the amount of solvents required in their processing as well as ease of purification and of deprotection. The deprotection will also take place in a separate step with a following purification step.

For this purpose a series of reactions are available, but with the exception of catalytical hydrogenation, posing industrial problems of its own, these methods are occurring under violent, often strongly acidic or basic conditions, frequently giving rise to a series of side reactions, resulting in an impure product or demanding laborious purification.

The last steps in this relatively long series of synthesis steps may thus be a rather comprehensive deprotection to obtain the desired peptides, and, owing to the almost inevitable secondary reactions, rather laborious purification procedures are frequently required to provide a product with the desired high purity.

A dipeptide which has attracted great attention in recent years is L-Asp-L-Phe-methylester, also known as aspartame, and derivatives thereof which has found extended use as sweeteners. The chemical synthesis of aspartame is entailed with the above-mentioned drawbacks.

Attempts to avoid amino terminal protection in the production of aspartame and its derivatives have led to microbial termentation approaches, like the fermentation processes described in EP-A1-074095, EP-A2-102529 and EP-A2-154472. This technique is fundamentally different from synthetic approaches and relies on specific organisms for aspartame, arid is thus not gen rally applicable in connection with other

dipeptides. In addition, the yields are low and recovery from the fermentation broth laborious.

The above-mentioned shortcomings in the known processes for the production of aspartame are confirmed in EP-A2-269390. In this application a method for producing L-Asp-L-Phe-alkylesters is claimed which comprises reacting in a solvent medium L-aspartic acid alpha ester or L-aspartic acid alpha amide with L-phenylalanine alkyl ester in the presence of an enzyme, microorganism containing the enzyme, enzyme containing fraction of a microorganism, or enzyme immobilized on solid support, said enzyme being capable of forming L-aspartyl-L-phenylalanine alkyl ester by condensation of the L-aspartic acid alpha ester or L-aspartic acid alpha amides and L-phenylalanine alkyl ester.

It is seen that an enzyme must be used which has specific esterase or amidase activity against Asp, but not agains Phe. The only enzyme mentioned is the extracellular protease with esterolytic activity of Staphylococcus aureus V8.

While therefore the applicability of N- $\alpha$ -unprotected Asp-esters or amides is suggested - along with N-protected or  $\beta$ -esters or amides - the disclosure of one specific enzyme for the use in the production of a specific peptide supported only by one example where rather peculiar reaction conditions are used, viz. 5 times excess of substrate components, this reference does not by far provide a general teaching of the applicability of N-unprotected substrate components in dipeptide synthesis catalyzed by amidase or esterase enzymes.

Thus, it is an obvious advantage in terms of overall process economy to be able to avoid protective groups, also on the amino and carboxy terminus. In some cases, it may be of interest to be able to produce a dipeptide having side-chain protection, but no terminal protection, and it will be shown that this is possible in the process according to this invention, starting from side-chain protected, but amino unprotected starting materials. In this case, the same advantages of mild reaction conditions and overall process economy may be obtained. If desired, the side-chain protective group may be removed by chemical or enzymatic means, generally under milder conditions than amino protective groups.

The enzyme catalyzed coupling reactions enabling the use of optionally side-chain unprotected amino acid derivatives and an optionally C-terminal unprotected B-component (nucleophile) are known. See e.g. the DK Patent Specification No. 155613 as well as the corresponding EP Patent Specification No. 17 485 (EP-B1-17485), incorporated herein by reference.

Briefly, EP-B1-17485 describes a process for producing peptides by reacting a substrate component selected from i.a. amino acid esters and amino acid amides with an amine component (nucleophile) selected from i.a. L-amino acid amides, L-amino acids or L-amino acid esters in the presence of an L-specific serine or thiol carboxypeptidase enzyme.

If a dipeptide is to be produced by the process of EP-B1-17485, the substrate component is obligatory an N-terminal protected amino acid derivative, and the constituent amino acid is obligatory an L-amino acid.

35

As described in EP-A1-278787, (incorporated by reference) and other applications claiming priority from DK appln. 725/87 filed on February 13, 1987 it was surprisingly found that the serine and thiol carboxypeptidases used in EP-B1-17485 are capable of utilizing N-unprotected amino acid esters or amides as a substrate component in controlled reactions for synthesis of dipeptides and dipeptide derivatives, and that it was possible to suppress a possible oligomerization of the substrate.

Admittedly, it has long been known that some endoproteases can catalyze oligomerization of certain N-unprotected amino acid esters with L-configuration, (Fruton,-J.S. Advances in Enzymology, 53: 239-306, 1982) but it has never been attempted to use this for production of dipeptides which are not simple dimers. Generally, the results of such oligomerizations have been a mixture of a series of oligomers, sometimes long. The degree of oligomerisation and complexity of the mixture depend on the solubility of the products formed. Also it should be mentioned that the mere fact that a given enzyme can hydrolyze a particular N- $\alpha$  unprotected amino acid derivative does not automatically lead to a similar ability to catalyze coupling reactions involving the same derivative. See the references cited by Andersen, A.J. in "Peptides, Structure and Function". Proc. of the ninth ann. peptide symposium, Eds. Deber, C.M. et al., Pierce (1985), p. 355.

For this reason the use of serine and thiol endoproteases for peptide synthesis has been limited to the use of amino and carboxy terminal protected starting materials, as exemplified by US-A-4.086.136, where e.g. papain, stembromelein, ficin, chymopapain and chymotrypsin are mentioned.

Furthermore, for these enzymes free amino acids have so far generally been regarded as unsuitable as amino components as noted by Y.W. Mitin et al., Int. J. Peptide Protein Res., Vol. 23 (1984), p. 528-534.

The above-mentioned amino and carboxy terminal protected starting materials are also mandatory if aspartate endoproteases e.g. pepsin are used as exemplified by US-A-3.972.773, and if metallo endoproteases are used, as exemplified by the synthesis of Z-AspPheOMe-PheOMe-salt in EP-A1-009585. In these condensation type reactions it is further mandatory that the substrate component is on the free  $\alpha$ -carboxylic acid form, as exemplified in EP-A2-220923.

The enzymatic condensation of L-amino acids with  $\alpha$ -aminophosphonic acids illustrated in EP-A2-209430 likewise makes use of an N- $\alpha$ -protected amino acid, e.g. BOC-Ala, BOC-Len or BOC-Phe, in the free carboxylic acid form as the substrate component.

The use of amino and carboxy terminal protected starting materials has also been considered mandatory for nonproteases, e.g. esterases with amidase activity, Blair West et al., Tetrahedron letters, Vol. 28. No. 15, p. 1629-32, (1987), who used porcine pancreatic lipase, Candida cylindracea lipase and pig liver esterase in organic media, optionally containing an aqueous buffer.

Cellulases in turn, have so far only been used synthetically for polymerisation condensation type reactions of completely free  $\beta$ -amino-acids as described by Kitazume, T. et al., J. Flourine Chem.  $\underline{36}$  - (1987), p. 225-236.

The synthesis of the diastereomeric dipeptides of DL, LD and DD-configuration as well as peptides containing β-amino acid residues from amino-unprotected substrate components has so far not been possible with carboxypeptidases except as described with relation to EP-A1-278787 nor in general with any proteolytical enzymes (Class EC 3.4). Some efforts have been made with a different class of enzymes, aminoacyl-t-RNA-synthetase (Class EC 6.1) as exemplified by EP-A1-086053. In this case a specific enzyme must be used for each type of amino acid residue, and furthermore, expensive Co-factors like ATP are required. At the same time, yields are very poor, so even though some product was isolated and identified, typically a ten fold excess of Co-factor and a hundred fold excess of nucleophile and up to a thousand fold excess of enzyme by weight was required.

A recent study by Gaertner et al., Proteins: Structure, Function and Genetics 3: 130-137 (1988) indirectly confirms the prejudice against using N- $\alpha$ -unprotected amino acids as substrate components in enzymatic peptide synthesis. Since a major problem earlier encountered is secondary hydrolysis of the newly synthesized product, an attempt was made to decrease water activity in the reaction medium by using organic solvents. Gaertner et al. reports dipeptide synthesis using chymotrypsin which had been chemically modified to enhance its solubility in organic media. Using a number of N- $\alpha$ -protected amino acid esters as substrates and amino acid amides as nucleophiles N- $\alpha$ -protected dipeptide amides were obtained in good yields in a benzene medium. Thus,  $\alpha$ -Bz-Lys-Phe-NH $_2$  was obtained in a yield of more than 98% by reacting  $\alpha$ -Bz-Lys-OMe with Phe-NH2. However, when using  $\epsilon$ -Z-Lys-OEt, i.e. a side-chain protected but N- $\alpha$ -unprotected lysine ester, no  $\epsilon$ -Z-Lys-Phe-NH $_2$  was formed. Gaertner et al do not comment on this result, but it indicates that they apparently believed that amino group protection of the substrate component was compulsory.

The present invention which represents a further development of the invention according to EP-A1-278787 resides on the surprising finding that the capability of utilizing  $N-\alpha$ -unprotected amino acid esters and amides as the substrate component in controlled reactions for synthesis of dipeptides and dipeptide derivatives is not limited to serine or thiol carboxypeptidases, but also possible with amidase or esterase enzymes generally, in particular serine endoproteases, thiol endoproteases, lipases and esterases.

Again, it was surprisingly found that also  $N-\alpha$ -unprotected amino acid derivatives of <u>D-configuration</u> can be used as substrates in these reactions, so that, in addition to LL-dipeptides, it is also possible to synthesize DL-dipeptides. The reaction rate for D-substrates, however, is generally somewhat lower than for L-substrates under uniform conditions, but the difference in rate is much smaller than for the corresponding N-protected amino acid esters, the D-substrate being reacted at a rate which is much smaller than the rate for the L-substrate; Purdie et al., Biochem. Biophys. Acta, 268 (1972), 523. There are, however great individual differences between the enzymes in this respect. Synthesis yields are often just as high with the unprotected D-substrates in relation to the unprotected L-substrates.

It is known that certain endoproteases are capable of utilizing a nucleophile component having D-configuration in reactions with N-protected substrate components. Thus, depending on the actual sequence it is possible to synthesize dipeptides having LL,- DL-, LD- or DD-configuration by the process according to the invention.

The process of the invention is thus characterized by reacting a substrate component, which is an amino acid derivative having the formula

wherein A is as defined above,  $R^1$  represents alkyl, aryl or aralkyl optionally substituted with inert substituents or an  $\alpha$ -des-amino fragment of an amino acid, and  $R^2$  and  $R^3$  are the same or different and each represents hydrogen, alkyl, aryl or aralkyl optionally substituted with inert substituents, with a nucleophile component selected from

(a) amino acids having the formula

H-B-OH

wherein B is an aminocarboxylic acid residue as defined above,

(b) amino acid amides having the formula

15

20

25

30

35

10

wherein B is an aminocarboxylic acid residue as defined above, and R<sup>2</sup> and R<sup>3</sup> have the above meaning, except that when R<sup>2</sup> represents hydrogen, R<sup>3</sup> may also represent hydroxy or amino.

(c) amino acid esters having the formula

H-B-OR4

wherein B is an aminocarboxylic acid residue as defined above, and R<sup>4</sup> represents alkyl, aryl or aralkyl, (d) optionally acid group protected straight chain or branched aminophosphonic acids or aminosulfonic acids having the formula

 $NH_2(CH_2)_xPO_3R^5R^6$  or  $NH_2(CH_2)_xSO_3R^7$ 

wherein R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> independently represent hydrogen, alkyl, aryl or aralkyl and x is 1-6, (e) amino acid aldehydes or ketones or derivatives thereof having the formula

H-B1-CY2-R8

wherein B¹ is as defined above, Y² is O or a functional derivative thereof, preferably a ketal, and R³ is H, alkyl, aryl or aralkyl, and

(f) amino alcohols having the formula

H-B1-CHY1-OH

40

45

wherein B1 and Y1 have the above meaning

in the presence of an amidase or esterase enzyme different from serine or thiol carboxypeptidases in solution or dispersion, and then, if desired, cleaving a present side-chain protecting group or protective group Y and/or, if desired, converting the resulting dipeptide derivative to a salt or hydrate.

Examples of useful amino acids include aliphatic amino acids, such as monoaminomonocarboxylic acids, e.g. glycine (Gly), alanine (Ala), valine (Val), norvaline (Nval), leucine (leu), isoleucine (iso-Leu) and norleucine (Nleu), hydroxy amino acids, auch as serine (Ser), threonine (Thr) and homoserine (homo-Ser), sulfur-containing amino acids, such as methionine (Met) or cystine (CysS) and cysteine (CysH), monoaminodicarboxylic acids, such as aspartic acid (Asp), glutamic acid (Glu) and amides thereof, such as asparagine (Asn) and glutamine (Gln), diaminomonocarboxylic acids, such as ornithine (Orn) and lysine (Lys), arginine (Arg), aromatic amino acids, such as phenylalanine (Phe) and tyrosine (Tyr), as well as heterocyclic amino acids, such as histidine (His), proline (Pro) and tryptophan (Trp). As examples of useful amino compounds of a more unusual structure may be mentioned penicillamine (Pen), aminophosphonic acids, such as alanine-phosphonic acid (AlaP), aminosulfonic acids, such as taurine (Tau),  $\omega$ -amino acids, such as  $\beta$ -alanine (BAla), iso amino acids, such as  $\alpha$ -methylalanin (Aib), amino acids substituted with inert substituents, e.g. halogen or nitro, or the aldehyde, ketones, ketals or alcohols derived from e.g. alanine. As mentioned, they may be included in D-form in the substrate component and they may also be present in D-form in the nucleophile component.

It will be understood that the definitions given for the group Y in the peptide derivative of the formula H-A-B-Y are reflected in the various nucleophile components, stated in claim 1. Thus, (b) and (c) both contain C-terminal blocking groups, while Y = H corresponds to an amino acid aldehyde and Y = alkyl, aryl or aralkyl corresponds to an amino ketone. If desired a functional derivative of an amino ketone may be used as nucleophile, e.g. a ketal, oxime or sulfite.

As in the process according to EP-A1-278787, the advantages of the process of the present invention over the mentioned known methods are minimum or no side chain protection, no N-protection of the substrate component which may have both D- and L-configuration, no risk of racemization, few synthesis steps and an expected relatively pure end product, which in combination provides an extremely simple and economic method of production.

Preferred substrate components are esters in which  $R^1$  is a straight or branched alkyl having 1 to 8 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, amyl, hexyl, heptyl and octyl, or the aralkyl group benzyl. Particularly expedient nucleophile components are amino acid amides, in which  $R^2$  is H, and  $R^3$  is H or  $C_1$ - $C_5$  alkyl, or amino acid esters in which  $R^4$  is a straight or branched alkyl having 1 to 6 carbon atoms such as the above-mentioned ones. As mentioned,  $R^1$  may be alkyl, aryl or aralkyl optionally substituted with inert substituents, e.g. hydroxy or nitro.

The invention also comprises the processes involving intermediate formation of a peptide containing the group

25

20

following which this group may be cleaved to form a carboxylic acid group. This cleavage may be catalyzed by another enzyme or the same enzyme as was used to form the peptide, albeit under different reaction conditions. Also C-terminal modifications of the group Y may be made.

Enzymes may also be used to cleave side-chain protective groups, applicable enzymes being proteolytic enzymes, lipases and esterases, according to the nature of the protective group, see "The peptides, Analysis, Synthesis, Biology" Vol 9, Special Methods in peptide Synthesis Part C. J.A. Glass, Enzymatic manipulation of Protecting Groups in Peptide Synthesis, Academic Press 1987.

As examples of enzymes possessing esterase and/or amidase activity, and therefore expected to be active as catalysts in the process according to this invention may be mentioned those listed in the table below

For a closer description of these enzymes, reference is made to i.a. Perlmann, G. E. et al., in Colowick, S. P. & Kaplan, N. O. (eds.) Methods of Enzym. 8 (1966) 19 (1970), 28 (1972), 35 (1975) and 45 (1976), Fruton, S., Adv. Enzymol. 53, p. 239, Wiley (1982), Abassi, A. et al. Biol. Chem. Hoppe-Seyler, 367, p. 441-45 (1986), Dixon, M. and Webb E. C. "Enzymes", 3rd ed. Longman Group (1979), Torrey, S. (ed.) in "Enzyme Technology, Recent Advances", Biotech, Rev. 2, Noyes Data Corporation (1983), and finally Laane, C., Tramper, S., Lilly, M. D. (eds.) "Biocatalysis in Organic Media", Elsevier (1987), Asano, Y. et al., Angew. Chem. 101, (1989), p. 511-512, Kitazume, T. et al., J. Fluorine Chem. 36 (1987), p. 225-236. all being incorporated by reference.

45

35

50

# TABEL I

# I. Proteases different from carboxypeptidases:

			Enzyme	(Abb)	Normal
10					Source
	A)	Thiolendo-			•
	•	proteases:	Papain	(P)	Papaya
15			Chymopapain	(CP)	Papaya
			Bromelain	(B)	Pineapple
			Ficin	(F)	Fig (Ficus)
20			Clostripain	(CL)	Clostridium
					histolyticum
		,			
	B)	Serineendo-			•
25		<pre>proteases:</pre>	Trypsin	(T)	Pancreas Pancreas
			Chymotrypsin	(CT)	Pancreas
			Elastase	(E)	Pancreas
30			Subtilisin	(S)	Bacillus
					licheniformis
					or subtilis
35			Thermitase	(TV)	Thermoacti-no-
35					myces
					vulgaris
			Proteinase K	(K)	Tritirachium
40			,		album
	•		Valyl-proteir	nase (VP)	Candida
					tropicalis
45			Post Prolin S	Specific	
			Endopeptidase	PPSE)	Flavo-
					bacterium
					meningo-
50					septicum
					•

	Achron	mobacter ly	ti-	
	cus Pr	rotease I	(AL-I)	Achromobacter
				lyticus
5	Endoprot	teinase Arg	C (AC)	Submaxil-
				laris glands
	Endoprot	teinase Lys	C (LC)	Lysobacter
10				enzymogenes
		Thrombi	n (TB)	Blood plasma
	C) Exopeptidases:			
15				
	Aminopeptidase (EC3.4.11)			Animal,
	particularly from			vegetable,
	Achromobacter sp.			or microbial
20				
	II. Other hydrolases actir	ng on ester	bonds	
25	Carboxylesterase (EC	C.3.1.1.1)		Liver
	Arylhydrolase (EC	C.3.1.1.2)		Plasma
	Triacylglycerollipase (EC	C.3.1.1.3)		Animal,
	particularly from			vegetable,
30	Porcine Pancreas or			or micro-
	Candida cylindracea or			tial
	Lipolase (NOVO); (Aspergi	illus sp.)		
35				
	Acetic ester			
	acetylesterase (EC	C.3.1.1.6)		Animal
		•		tissue
40	Arylglycerol lipase (EC	C.3.1.1.23)		Animal or
				vegetable
	III Glycosidases			
46	•			
45		C.3.2.1.4)		Animal,
	particularly from			vegetable,
	Trichoderma viride or			or micro-
50	Aspergillus niger			bial

The presently preferred enzymes are trypsin, chymotrypsin, subtilisin, elastase, papain, chymopapain, clostripain, porcine pancreatic lipase and Candida cylindracea lipase.

The enzyme used may also be chemically modified or be a biosynthetic mutant of a natural form.

As illustrated more fully below, the process of the invention is rather simple.

The reaction may be performed in an aqueous reaction medium, if desired containing up to 90%, preferably up to 60% of a polar organic solvent which is miscible with water, and compatible with the enzyme under the conditions specified. Preferred solvents are lower alcohols, dimethyl formamide, dim thyl

Achromobacter lyticus Protease I (AL-I) Achromobacter lyticus Endoproteinase ArgC (AC) Submaxillaris glands Endoproteinase LysC (LC) Lysobacter enzymogenes 10 Thrombin (TB) Blood plasma C) Exopeptidases: 15 Aminopeptidase (EC3.4.11) Animal, particularly from vegetable, Achromobacter sp. or microbial 20 II. Other hydrolases acting on ester bonds Carboxylesterase (EC.3.1.1.1) Liver 25 Arylhydrolase (EC.3.1.1.2) Plasma Triacylglycerollipase (EC.3.1.1.3) Animal, particularly from vegetable, 30 Porcine Pancreas or or micro-Candida cylindracea or tial Lipolase (NOVO); (Aspergillus sp.) 35 Acetic ester acetylesterase (EC.3.1.1.6) Animal tissue Arylglycerol lipase (EC.3.1.1.23) Animal or 40 vegetable III Glycosidases 45 Cellulase (EC.3.2.1.4) Animal, particularly from vegetable, Trichoderma viride or or micro-Aspergillus niger bial

The presently preferred enzymes are trypsin, chymotrypsin, subtilisin, elastase, papain, chymopapain, clostripain, porcine pancreatic lipase and Candida cylindracea lipase.

The enzyme used may also be chemically modified or be a biosynthetic mutant of a natural form.

As illustrated more fully below, the process of the invention is rather simple.

50

55

The reaction may be performed in an aqueous reaction medium, if desired containing up to 90%, preferably up to 60% of a polar organic solvent which is miscible with water, and compatible with the enzyme under the conditions specified. Preferred solvents are lower alcohols, dimethyl formamide, dimethyl

products, the yields were determined on the basis of the ratio between the integrated areas below the peaks in the elution chromatogram, corresponding to the product respectively the reactant which absorbs at the wavelength concerned.

The reaction conditions in the preparative examples 14-17 are described in the individual examples. The reactions were followed on analytical HPLC as described. The enzyme concentrations are generally lower and the reaction times longer than in the corresponding analytical examples, but no attempt to optimize the reaction conditions has been made.

## Example 1

10

	Trypsin <sup>a</sup> ) catalyzed synthesis of L,L-dipeptide amides with L-Arginine ethyl ester (50 mM) as substrate and L-amino acid amides as nucleophiles at various concentrations in water at pH 8.5					
15 -	Nucleophile	(conc.)	Product	Yield		
	Leucine amide	(0.2 M)	ArgLeuNH₂	20%		
	Leucine amide	(0.7 M)	ArgLeuNH₂	32%		
i	Methionine amide	(0.25 M)	ArgMetNH₂	31%		
	Methionine amide	(0.5 M)	ArgMetNH₂	52%		
20	Methionine amide	(1.0 M)	ArgMetNH <sub>2</sub>	90%		
	Serine amide	(0.5 M)	ArgSerNH₂	45%		
	Tyrosine amide	(0.5 M)	ArgTyrNH₂	46%		

a) 10 uM

25

## Example 2

35

40

45

50

		pH 8.5		
Substrate	Nucleophile	(conc.)	Product	Yield
D-argOEt	L-Leucine amide	(0.2 M)	argLeuNH <sub>2</sub>	20%
D-argOEt	L-Leucine amide	(1.0 M)	argLeuNH <sub>2</sub>	30%
D-argOEt	L-Methionine amide	(0.5 M)	argMetNH₂	68%
L-ArgOEt	D-methionine	(1.0 M)	ArgmetNH₂	5%

a) 10 uM

### Example 3

_	Trypsin <sup>a</sup> ) catalyzed synthesis of L,L-dipeptide amides using L-amino acid amides (0.5 M) as nucleophiles
o .	and L-Lysine or Histidine ethyl ester (50 mM) as substrate in water at pH 8.5

	·	<u> </u>	·-
Substrate	Nucleophile	Product	Yield
LysOEt	Methionine amide	LysMetNH <sub>2</sub>	81%
LysOEt	Tryptophane amide	LysTrpNH₂	32%
LysOEt	Alanine amide	LysAlaNH <sub>2</sub>	5%
HisOEt	Methionine amide	HisMetNH₂	62%

a) 10 uM

15

10

## Example 4

Alpha-Chymotrypsin <sup>a</sup>) catalyzed synthesis of L,L-dipeptide amides using L-Tyrosine ethyl ester (50 mM) as substrate and L-amino acid amides as nucleophiles in water

Nucleophile	(conc.)	pН	Product	Yield
Leucine amide	(0.2 M)	9.0	TyrLeuNH₂	68%
Arginine amide	. (0.4 M)	8.5	TyrArgNH₂	90%
Serine amide	(0.4 M)	8.5	TyrSerNH₂	75%

a) 5 uM

30

25

## Example 5

Alpha-Chymotrypsin <sup>a</sup>) catalyzed synthesis of L,D-dipeptide amides using L-Tyrosine ethyl ester (5 or 50 mM) as substrate and D-amino acid amides as nucleophiles in water

Nucleophile	(conc.)	рН	Product	Yield
D-leucine amide	(0.2 M)	9.0	TyrLeuNH₂	17% <sup>b</sup> )
D-isoleucine amide	(0.3 M)	9.0	TyrileNH <sub>2</sub>	23% <sup>b</sup> )
D-serine amide	(0.4 M)	8.5	TyrserNH <sub>2</sub>	35%

<sup>a</sup>) 5 uM

b) 5 mM substrate

45

40

50

### Example 6

5	Alpha-Chymotrypsin catalyzed synthesis of D,L-dipeptide amides using D-tyrosine ethyl ester (50 mM) as substrate and L-Leucine amide as nucleophiles in water at pH 9.0					
	Nucleophile	(conc.)	Product	Yield <sup>c</sup> )		
	L-Leucine amide L-Leucine amide	(0.2 M) (0.3 M)	D,L-tyrLeuNH₂ D,L-tyrLeuNH₂	40% <sup>a</sup> ) 68% <sup>b</sup> )		

<sup>a</sup>) 50 uM enzyme

b) 100 uM enzyme

c) Prolonged reaction time - days

Example 7

10

15

30

35

40

45

50

20 Alpha-Chymotrypsin <sup>a</sup>) catalyzed synthesis of L,L- and L,D-dipeptide amides and esters using different L-amino acid esters (50 mM) as substrates and L- or D-amino acid esters (0.8 M) or amides as nucleophiles at pH 8.5 Substrate Nucleophile Solvent **Product** Yield<sup>d</sup>) L-PheOEt L-ArgNH<sub>2</sub>b) 25 Water PheArgNH<sub>2</sub> 82% L-TyrOEt L-SerOEt Water **TyrSerOEt** 48%c) L-TyrOBzl L-SerOEt 30% DMF **TyrSerOEt** 40%°) L-TyrOBzI L-SerOMe 30% DMF **TyrSerOMe** 39%°) L-TyrOBzI D-serOMe 30% DMF TyrserOMe 21%°)

<sup>a</sup>) 5 uM

b) 0.4 M nucleophile

c) at 90% conversion

d) hydrolysis/diketopiperazine formed due to chemical instability of product was observed under these conditions in amounts of 15-35% and is not included in the yields reported.

Example 8

Subtilisin A <sup>a</sup>) catalyzed synthesis of sidechain protected L-Aspartyl-D-alanyl amide using L-Aspartyl diesters (0.1 M) as substrates and D-alanine amide as nucleophile at pH 8.5 Substrate Nucleophile Solvent **Product** Yield (conc.) L-Asp(OEt)2 (1.0 M)Water Asp(OEt)alaNH<sub>2</sub> 9% L-Asp(OEt)2 (2.0 M)Water Asp(OEt)alaNH<sub>2</sub> 24% L-Asp(OBzI)2b) (0.5 M)30% DMSO Asp(OBzl)alaNH<sub>2</sub> 8% L-Asp(OBzI)2b) (1.0 M)**30% DMSO** Asp(OBzI)alaNH2 20%

a) 5 uM

b) 50 mM substrate, 20 uM enzyme

# Example 9

5		nthesis of L,L-amides using am nino acid amide (0.5 M) as nucle		
	Substrate	Nucleophile	Product	Yield
	L-ValOBzl	L-Aroinine amide	ValArgNHa	59%

<sup>a</sup>) 40 uM

# Example 10

15

20

Synthesis of L,L-dip (50 mM) as su	peptide amides cata obstrates and L-amir	lyzed by papaya thiole no acid amides (0.8 M)	ndoproteases <sup>a</sup> ) using a as nucleophiles in wate	mino acid ester er at pH 8.5
Enzyme .	Substrate	Nucleophile	Product	Yield
Papain	LysOEt	AlaNH <sub>2</sub>	LysAlaNH₂	60%
Papain	LysOMe	AlaNH <sub>2</sub>	LysAlaNH <sub>2</sub>	55%
Chymopapain	LysOEt	AlaNH <sub>2</sub>	LysAlaNH <sub>2</sub>	23%
Chymopapain	LvsOMe	AlaNH <sub>2</sub>	LvsAlaNH <sub>2</sub>	34%

a) 100 uM, 2mM EDTA, 10 mM Cysteine

## Example 11

30

35

40

Clostripain <sup>a</sup> ) catalyzed synthesis of L,L-dipeptide amides and esters with L-Arginine ethyl ester as substrate (50 mM) and L-amino acid amides as nucleophiles at pH 8.5						
Nucleophile (conc.) Solvent Product Yield						
L-Methionine amide	(0.5 M)	Water	ArgMetNH₂	38%		
L-Phenylalanine amide	(0.2 M)	30% EtOH	ArgPheNH₂	6%		
L-Phenylalanine amide	(0.6 M)	30% DMF	ArgPheNH₂	65%		

a) 5 uM enzyme, 50 mM CaCl<sub>2</sub>, 10 mM DTT, pH adjusted with TEA

50

45

### Example 12

Porcine Pancrease Lipase a) catalyzed synthesis of L,L-dipeptide amides using L-amino acid ethyl esters (50 mM) as substrates and L-amino acid amides as nucleophiles in 30% EtOH at pH 8.5

Substrate	Nucleophile	(conc.)	Product	Yield
L-TrpOEt	L-MetNH <sub>2</sub>	(1.5 M)	TrpMetNH₂	71%
L-TrpOEt	L-MetNH <sub>2</sub>	(1.0 M)	TrpMetNH₂	54%
L-TyrOEt	L-SerNH₂	(1.5 M)	TyrSerNH₂	69%
L-MetOEt	L-MetNH <sub>2</sub> b)	(1.0 M)	MetMetNH <sub>2</sub>	31%°)

a) 500 uM

- b) Reaction in pure water
- c) At incomplete conversion

#### Example 13

25

Candida Cylindracea Lipase a) catalyzed synthesis of L,L-dipeptide amides using L-amino acid ethyl esters (50 mM) as substrates and L-amino acid amides as nucleophiles in 30% EtOH at pH 8.5

Substrate	Nucleophile	(conc.)	Product	Yield
L-TrpOEt	L-MetNH₂	(1.5 M)	TrpMetNH <sub>2</sub>	75% <sup>b</sup> )
L-TyrOEt	L-SerNH₂	(1.5 M)	TyrSerNH <sub>2</sub>	50% <sup>b</sup> )

a) 1000 uM, prolonged reaction time

### Example 14

## Preparative synthesis of L,L-TryptophanylMethionine amide, TrpMetNH<sub>2</sub>

#### Procedure

L-Tryptophane ethyl ester hydrochloride (4.0 g, 15 mmol) and L-Methionine amide hydrochloride (55.7 g, 300 mmol) were dissolved in 195 ml H<sub>2</sub>O and 90 ml ethanol, and pH was adjusted to 8.5 with sodium hydroxide. The reaction was initiated by addition of 0.8 g of crude Porcine Pancreatic Lipase and was kept at pH 8.5 for the duration of the reaction. The remainder of the substrate (4.0 g, 15 mmol) was added after 5 hours and the reaction continued overnight. It was then stopped by adjusting pH to 3 with HCl-solution.

The mixture was then diluted, ethanol was removed by evaporation under reduced pressure, and the mixture was filtered. The filtrate was purified by RP-preparative HPLC (Waters Prep LC/System 500A) using two columns (5.7 x 30 cm) packed with 60 um C-18 particles and 5 mM HCl/ethanol mixtures as eluent.

Collected fractions containing pure product were concentrated under reduced pressure and finally

This procedure gave 4.78 g of L,L-Tryptophanylmethionine amide hydrochloride (12.9 mmol, 43%) as an amorphous powder.

## Identification

The product was identified as the hydrochloride containing 10.3% (w/w) of chloride.

Amino acid analysis showed the absence of free amino acids and gave the following results after acid hydrolysis:

Met (1.00)

Trp (1.00)

14

10

15

20

b) Versus hydrolysis at less than 50% conversion

Specific optical rotation in 50% MeOH, c = 0.2 using the sodium D-line was found to be +40.0 at 20 °C.

#### Purity

HPLC-purity: 92.4% (Novapak 4 um C-18, 0.1 M ammonium phosphate, pH 3.0/acetonitrile, 220 nm) Water content by Karl Fisher: 5.3% (w/w)

Quantization of the alpha-amino group by reaction with Trinitrobenzene sulphonic acid and UV-detection: 75.8% (w/w).

Peptide content by UV-quantization: 88.3% (w/w) (281 nm, Trp-absorbance in MeOH: 0.1 N KOH (1:1))

Example 1

10

Preparative synthesis of L,D-Tyrosylserin amide, TyrserNH<sub>2</sub>

## 15 · Procedure

L-Tyrosine ethyl ester hydrochloride (2.5 g, 10 mmol) and D-serine amide hydrochloride (17.5 g, 100 mmol) were dissolved in 200 ml of water, and pH was adjusted to 8.5 with sodium hydroxide. The reaction was initiated by addition of 50 mg of alpha-chymotrypsin and was kept at pH 8.5 for the duration of the reaction. After 30 minutes precipitation of free tyrosine began. The remainder of the substrate (5.0 g, 20 mmol) was added in two portions of 2.5 g during 1 hour. The reaction was stirred for two hours and was then stopped by adjusting pH to 3 with HCl-solution.

The formed tyrosine was filtered off, and the filtrate was purified by RP-preparative HPLC (Waters Prep LC/System 500A) using two columns (5.7 x 30 cm) packed with 20 uM C-18 particles and 50 uM acetic acid as an eluent.

Collected fractions containing pure product were concentrated under reduced pressure and finally freeze dried with addition of aqueous HCI.

This procedure gave 2.8 g of L,D-Tyrosylserine amide hydrochloride (9.2 mmol, 31%) as an amorphous powder.

# Identification

30

The product was identified as the hydrochloride containing 16.0% (w/w) of chloride.

Amino acid analysis showed the absence of free amino acids, but following acid hydrolysis gave the following results:

Ser (1:10)

Tyr (0.90)

Specific optical rotation in 50% MeOH, c = 0.3 using the sodium D-line was found to be +58.0 at 20 °C.

## 40 Purity

HPLC-purity: 97.4% (Novapak 4 um C-18, 0.1 M ammonium phosphate, pH 3.0/acetonitrile, 220 nm) Water content by Karl Fisher: 1.8% (w/w).

Quantization of the alpha-amino group by reaction with Trinitrobenzene sulphonic acid and UV-detection: 81% (w/w).

Example 16

Preparative synthesis of D,L-tyrosylLeucin amide, tyrLeuNH2

#### Procedure

D-tyrosine ethyl ester hydrochloride (3.5 g, 14 mmol) and L-Leucin amide hydrochloride (14 g, 84 mmol) were dissolved in 246 ml of 0.1 M KCl and pH was adjusted to 9.0 with sodium hydroxide. The reaction was initiated by addition of 0.7 g of alpha-chymotrypsin and stirred for two days at room temperature. pH was kept at 9.0 for the duration of the reaction. The reaction was stopped by adjusting pH to 3 using HCl-solution.

The formed tyrosine was filtered off, and the filtrate was purified by RP-preparative HPLC (Waters Prep LC/System 500A) using two columns (5.7 x 30 cm) packed with 20 uM C-18 particles and 5 mM HCl as an eluent.

Collected fractions containing pure product were concentrated by evaporation under reduced pressure and finally freeze dried.

This procedure gave 2.50 g of D,L-tyrosylLeucine amide hydrochloride (7.6 mmol, 54%) as an amorphous powder.

#### Identification

10

The product was identified as the hydrochloride containing 9.8% (w/w) of chloride.

Amino acid analysis showed the absence of free amino acids, but following acid hydrolysis gave the following results:

Tyr (0,98)

5 Leu (1.03)

Specific optical rotation in water, c = 0.1 using the sodium D-line was found to be -129.4° at 20°C.

### Purity

20 HPLC-purity: 92.9% (Novapak 4 um C-18, 0.1 M ammonium phosphate, pH 3.0/acetonitrile, 220 nm) Water content by Karl Fisher: 6.8% (w/w).

Quantization of the alpha-amino group by reaction with Trinitrobenzen sulfonic acid and UV-detection: 74.9%

UV-quantization: 74.9% (Tyrosine phenolate absorbance at 293 nm, in 0.1 M KOH)

25

40

Example 17

Preparative synthesis of L,L-ArginylMethionine amide, Arg-MetNH<sub>2</sub>

## 30 Procedure

L-Arginine ethyl ester dihydrochloride (4.1 g, 15 mmol) and L-Methionine amide hydrochloride (55.4 g, 300 mmol) were dissolved in 300 ml of water, and pH was adjusted to 8.5 with sodium hydroxide. The reaction was initiated by addition of 50 mg of trypsin. pH was kept at 8.5 for the duration of the reaction. The remainder of the substrate (8.2 g, 30 mmol) was added during one hour. The reaction was then stopped by adjusting pH to 3 using HCl-solution.

The reaction mixture was then diluted and purified by successive cation exchange on a DOWEX A650 Wx4 and a CM-Sepharose 6B column using ammonium acetate and NaCl/HCl salt gradients, respectively, and was finally desalted.

Collected fractions containing pure product were concentrated under reduced pressure and finally freeze dried.

This procedure gave 10.7 g of L,L-ArginylMethionine amide dihydrochloride (28.3 mmol, 63%) as a white amorphous powder.

### 45 Identification

Less than 0.2% (w/w) of acetate and 22.9% (w/w) of chloride were measured, so the product was present as a dihydrochloride.

Amino acid analysis showed the absence of free amino acids, but following acid hydrolysis gave the following results:

Arg (1.00)

Met (0.80)

Specific optical rotation in 50% MeOH, c = 0.2 using the sodium D-line was found to be + 19.5° at 20°C.

### 55 Purity

HPLC-purity: 95.1% (Novapak C-18, 0.1 M ammonium phosphate containing alkylsulfonate, pH 4.5/acetonitrile, 220 nm)

Water content by Karl Fisher: 9.1% (w/w).

Peptide content by amino acid analysis: 72% (w/w) based on Arginine.

### Example 18

5

Synthesis of L,L-Methionyl-Methionine amide catalyzed by Eupergit C immobilized Porcine Pancreatic Lipase <sup>a</sup>) using L-Methionine ethyl ester as substrate and L-Methionine amide as nucleophile at pH 8.5 in water and water/organic homogeneous mixtures.

10

Conc. of substrate	Nucleophile	%	Organic solvent	Yield <sup>b</sup> )
50 mM	1.0 M	0	-	68%
100 mM	0.5 M	30	Isopropanol	26%

15

<sup>a</sup>) Porcine Pancreatic Lipase was immobilized on Eupergit C using the procedure recommended by the manufacturer to a final concentration corresponding to approx. 400 μM on the gel by activity assay.

20

b) The reaction mixtures with volumes of 1-3 reaction bed volumes were recirculated over the column packed with enzyme gel until full conversion of the substrate as determined by HPLC (0.5-2 days) while pH was being kept constant by pH-stat control.

25

### Example 19

30

Porcine Pancreatic Lipase <sup>a</sup>) and alpha-chymotrypsin <sup>a</sup>) catalyzed synthesis of L,L-Tryptophanyl-Alanine-tert-butylester in pure organic solvents with L-Tryptophane ethyl ester (50 mM) as substrate and L-Alanine-tert-butylester (0.3 M) as nucleophile, both in saltfree form.

35

40

Enzyme *)	Enzyme <sup>a</sup> ) Solvent		Yield <sup>c</sup> )	
PPL	CH <sub>2</sub> Cl <sub>2</sub> /n-Hexane (1:3)	30%	13%	
СТ	CH <sub>2</sub> Cl <sub>2</sub> /n-Hexane (1:3)	56%	17%	
PPL	CH₂Cl₂	7%	10%	
СТ	CH <sub>2</sub> Cl <sub>2</sub>	50%	3%	
PPL b)	CH <sub>2</sub> Cl <sub>2</sub> /Isooctane (1:1)	82% <sup>b</sup> )	26%	

 $<sup>^{\</sup>rm a})$  500-2000  $\mu{\rm M}$  freezedried enzyme containing moisture was added directly to the mixture, which was stirred for 24 hours.

45

50

b) In this case, 500 μM enzyme and 3 days of reaction time were applied.

c) Conversion of starting material and yield versus hydrolysis was determined by HPLC of samples quenched with DMF, evaporated and redissolved in DMF/acid water. Controls showed neither conversion nor yield.

## Example 20

5	Alpha-chymotrypsin <sup>a</sup> ) catalyzed synthesis of sidechain protected L,L-dipeptide amides with L-Tyrosine or L-Phenylalanine ethyl esters (50 mM) as substrates and L-S-Acetamidomethylcystein amide (0.6 M) as nucleophiles in water at pH 8.5.					
	Substrate	Product	Yield			
10	L-Tyrosine ethyl ester L-Phenylalanine ethyl ester	TyrCys(-SAcm)NH₂ PheCys(-SAcm)NH₂	62% 78%			

a) 5 μM

## Example 21

20	Alpha-chymotrypsin <sup>a</sup> ) catalyzed synthesis of L,L-Dipeptide alcohols using L-Tyrosine and L-Phenylalanine ethyl esters (50 mM) as substrates and L-Amino acid alcohols (0.5 M) as nucleophiles in water at pH 8.5.					
	Substrate	Nucleophile	Product	Yield		
	L-TyrOEt	L-MetCH <sub>2</sub> OH	TyrMetCH₂OH	42%		
	L-TyrOEt	L-LeuCH <sub>2</sub> OH	TyrLeuCH₂OH	46%		
25	L-PheOEt	L-MetCH <sub>2</sub> OH	PheMetCH₂OH	60%		

a) 10 µM

## Example 22

35

40

45

50

Synthesis of L,I	Synthesis of L,L-dipeptides catalyzed by thiolendoproteases <sup>a</sup> ) using amino acid ethyl esters (50 mM) as substrate and free L-Amino acids as nucleophiles in water at pH 8.5.							
Enzyme	Substrate	(conc.) Product		Yield <sup>b</sup> ) <sup>c</sup> )				
Ficin Papain Ficin Papain	ArgOEt ArgOEt LysOEt LysOEt	ArgOH ArgOH AlaOH AlaOH	(1.0 M) (1.0 M) (1.5 M) (1.5 M)	ArgArgOH ArgArgOH LysAlaOH LysAlaOH	6% 7% 5% 6%			

 $<sup>^{\</sup>rm a})$  100  $\mu\text{M},$  2 mM EDTA, 0.1 M KCl, 5 mM DTT or 10 mM cysteine.  $^{\rm b})$  Determined vs. hydrolysis via a standard at less than 50% conversion.

c) Controls without enzyme showed no detectable aminolysis under the conditions reported.

### Example 23

Trypsin <sup>a</sup>) catalyzed synthesis of L,L-dipeptide amides with Arginine-paranitroanilide (10 mM) as substrate and L-Amino acid amides (0.3 M) as nucleophiles in 40% DMF at pH 8.5.

Nucleophile Product Yield <sup>b</sup>)

Nucleophile	Product	Yield <sup>b</sup> )
Methionine amide	ArgMetNH <sub>2</sub>	45%
Leucine amide	ArgLeuNH₂	31%
Tyrosine amide	ArgTyrNH₂	14%

a) 5 µM

10

15

30

35

40

45

Example 24

Papain a)b) catalyzed synthesis of L,L-Lysyl-Alanine amide using L-Lysine ethyl ester (50 mM) as substrate and L-Alanine amide (0.8 M) as nucleophile in water at various pH-values.

PH

Yield c)

6.5

21%
4.5

4.5

47%

<sup>a</sup>) 50 μM, 2 mM EDTA, 10 mM Cysteine.

Example 25

Alpha-chymotrypsin <sup>a</sup>) and clostripain <sup>b</sup>) catalyzed synthesis of L,L-dipeptide esters using L-Amino acid ethyl esters (50 mM) as substrates and L-Amino acid ethyl or tert-butyl-esters as nucleophiles in water at pH 7.5 and 8.5.

	Enzyme	Substrate	Nucloephile	(conc.)	Product	Yield
	СТ	TrpOEt	AlaOtBu	(0.8 M)	TrpAlaOtBu	12%
1	CT	TrpOEt	ValOEt	(M 8.0)	TrpValOEt	18%
1	CL	ArgOEt	MetOEt	(1.0 M)	ArgMetOEt	33% °)

<sup>a</sup>) 5 μM, 0.1 M KCl, pH 7.5.

b) Determined vs. hydrolysis via a standard at less than 80% conversion.

b) At prolonged reaction time; less than 50% conversion.

c) Determined vs. hydrolysis using a standard and corrected for incomplete conversion.

b) 10 μM, 50 mM CaCl<sub>2</sub>, 10 mM DTT, pH 8.5 adjusted with TEA.

c) Determined at less than 50% conversion.

## Example 26

Porcine Pancreatic Lipase <sup>a</sup>) and Lipolase (Novo)(LIP) <sup>a</sup>) and Rhizopus Arrhizus Lipase (RA) <sup>b</sup>) catalyzed synthesis of L,L-Methionyl-Methionine amide using different L-Methionine esters as substrates and L-Methionine amide as nucleophile in various aqueous/organic solvent homogeneous mixtures at pH 8.5 and 1.0 M nucleophile, unles otherwise indicated.

	Ester				Organic		
Enzyme	substrate	(con	<del>c.)</del>	3	solvent	Yield	e)
PPL C)	Ethyl	(50	mM)	0	•	55%	
PPL d)	Ethyl	(50	mM)	0	-	361	
PPL	Ethyl	(150	mM)	0	•	42%	
PPL	Ethyl	(200	mM)	15	Dimethoxy Ethane	201	
PPL	Ethyl	(150	mM)	30	Isopropanol	36%	
PPL	Ethyl	(50	mM)	90	Ethylene Glycol	428	
PPL	n-Propyl	(50	mM)	0	•	55%	
PPL	n-Hexyl	(50	mm)	0	-	39%	
LIP	Ethyl	(50	mM)	0	•	478	
LIP	Ethyl	(50	mM)	15	Dimethoxy Ethane	35%	
LIP	n-Hexyl	(50	mM)	0	-	321	
RA	Ethyl	(50	mM)	30	Ethanol	23%	

Mu 2000 - Mu 1000 (4

40

45

50

55

b) 50 µм

c) pH 9.0

d) At 0.25 M nucleophile

e) Various minor amounts of deamidation of product was noted under these conditions and is not included in the yields reported.

#### Example 27

5	Trichoderma Viridae Cellulase catalyzed synthesis of L,L-TyrGlyNH <sub>2</sub> using L-Tyrosine ethyl ester as substrate and Glycine amide as nucleophile in water.							
	Substrate	(conc.)	Nucleophile	(conc.)	Product	Yield		
o	TyrOEt <sup>a</sup> ) TyrOEt <sup>b</sup> ) TyrOiPr <sup>b</sup> )	(20 mM) (10 mM) (10 mM)	GlyNH₂ GlyNH₂ AlaNH₂	(0.6 M) (0.8 M) (1.5 M)	TyrGlyNH₂ TyrGlyNH₂ TyrAlaNH₂	23% °) 34% °) 52% <sup>d</sup> )		

- a) 1000 µM crude enzyme, pH 8.5
- b) 500 μM crude enzyme, pH 8.0
- c) Determined vs. hydrolysis at less than 30% conversion and corrected for hydrolysis and aminolysis found in controls at similar conditions.
- <sup>d</sup>) Complete enzymatical and no spontaneous conversion was observed under the conditions employed

### Claims

20

25

30

35

40

45

50

55

1. A process for producing dipeptides or structurally related compounds having the general formula

H-A-B-Y

wherein A represents an optionally side-chain protected L-or D- $\alpha$ -amino acid residue or  $\omega$ -amino acid residue and B represents an optionally side-chain protected L- or D- $\alpha$ -aminocarboxylic acid residue which may be the same as or different from A, an L- or D-aminophosphonic acid residue or L- or D-aminosulfonic acid residue or the corresponding  $\omega$ -amino acids or salts and hydrates thereof, and Y is OH, H, alkyl, aryl, aralkyl or a C-terminal blocking group, with the proviso that A can not be Asp or Glu when B is Phe and Y is alkyl or BY represents an amino alcohol residue

B1-CHY1-OH

wherein B¹ is a decarboxy derivative of the aminocarboxylic acids as defined with relation to B, and Y¹ is H, alkyl, aryl or aralkyl, **characterized** by reacting a substrate component, which is an amino acid derivative having the formula

H-A-OR<sup>1</sup> or H-A-N

wherein A is as defined above,  $R^1$  represents alkyl, aryl or aralkyl optionally substituted with inert substituents or an  $\alpha$ -des-amino fragment of an amino acid, and  $R^2$  and  $R^3$  are the same or different and each represents hydrogen, alkyl, aryl or aralkyl optionally substituted with inert substituents, with a nucleophile component selected from

(a) amino acids having the formula

н-в-он

wherein B is an aminocarboxylic acid residue as defined above,

#### (b) amino acid amides having the formula

H-B-N R 2

wherein B is an aminocarboxylic acid residue as defined above, and R<sup>2</sup> and R<sup>3</sup> have the above meaning, except that when R<sup>2</sup> represents hydrogen, R<sup>3</sup> may also represent hydroxy or amino, (c) amino acid esters having the formula

H-B-OR4

5

10

15

20

25

30

35

40

wherein B is an aminocarboxylic acid residue as defined above, and R4 represents alkyl, aryl or aralkyl,

(d) optionally acid group protected straight chain or branched aminophosphonic acids or aminosulfonic acids having the formula

NH2(CH2)xPO3R5R6 or NH2(CH2)xSO3R7

wherein  $R^5$ ,  $R^6$  and  $R^7$  independently represent hydrogen, alkyl, aryl or aralkyl and x is 1-6 (e) amino acid aldehydes or ketones or derivatives thereof having the formula

H-B1-CY2-R8

wherein B<sup>1</sup> is as defined above, Y<sup>2</sup> is O or a functional derivative thereof, preferably a ketal, and R<sup>8</sup> is H, alkyl, aryl or aralkyl, and

(f) amino alcohols having the formula

H-B1-CHY1-OH

wherein B1 and Y1 have the above meaning

in the presence of an amidase or esterase enzyme different from serine or thiol carboxypeptidases in solution or dispersion, and then, if desired, cleaving a present side-chain protecting group or protective group Y and/or, if desired, converting the resulting dipeptide derivative to a salt or hydrate.

- A process according to claim 1, characterized by using an enzyme with esterase or amidase activity selected from serine or thiolendoproteases, lipases, esterases and glycosidases.
  - A process according to claim 1 or 2, characterized in that the enzyme used has been chemically modified or is a biosynthetic mutant of a natural form.
- 45 4. A process according to any of the preceding claims, characterized by using an immobilized enzyme.
  - 5. A process according to any of the preceding claims, **characterized** by using an aqueous reaction solution or dispersion containing 0-90%, preferably 0-60%, of a polar water miscible organic solvent and having a pH value of 3-11, preferably 5-10.5, more preferably 6-10, in particular 7-9.5.
  - 6. A process according to claim 5, **characterized** in that the organic solvent is selected from alkanols, dimethyl sulfoxide, dimethyl formamide, dimethoxy ethane and ethylene glycol.
- 7. A process according to any of claims 1 to 4, characterized by using an organic reaction solution or dispersion containing 0-10% of water.
  - 8. A process according to claim 7, characterized by using an unpolar organic solvent, preferably selected from dialkyl ethers, ethyl acetate, ethyl propionate, octanes, heptanes, hexanes, petroleum

ether and methylene chloride.

- 9. A process according to claim 7, characterized by using a liquid substrate or nucleophile component which may also serve as the organic solvent.
- 10. A process according to any of the preceding claims, characterized by using as substrate component a D- or L-amino acid ester selected from benzyl esters or straight or branched C<sub>1</sub>-C<sub>8</sub> alkyl esters optionally substituted with inert substituents.
- 10. 11. A process according to any of the preceding claims, characterized by using as nucleophile component an amino acid amide having the formulae

H-B-NHR3

- wherein R3 is hydrogen or C1-C3 alkyl and B is an L- or D-amino carboxylic acid residue.
  - 12. A process according to any of claims 1 to 10, characterized by using as nucleophile component an ester having the formula
- 20 H-B-OR⁴

30

wherein B is a L- or D-aminocarboxylic acid residue and R4 is C1-C3 alkyl.

- 13. A process according to any of the preceding claims, characterized in that the resulting dipeptide includes one or more C-terminal protective groups Y, and that the group or groups are cleaved enzymatically, either by means of the same enzyme as was used in the preceding reaction or by means of an enzyme having a different ester or amide specifically.
  - 14. A process according to any of the preceding claims, characterized in that the resulting dipeptide includes one or more side-chain protective groups and that the group or groups are cleaved enzymatically, preferably by means of an esterase or lipase or proteolytical enzyme.

#### Patentansprüche

 Verfahren zur Herstellung von Dipeptiden oder strukturell verwandter Verbindungen der allgemeinen Formel

H-A-B-Y

in der A einen gegebenenfalls seitenkettengeschützten L-oder D-alpha-Aminosäurerest oder omegaAminosäurerest und B einen gegebenenfalls seitenkettengeschützten L- oder D-alpha-Aminocarbonsäurerest, der gleich oder verschieden von A sein kann, einen L- oder D-Aminophosphonsäurerest oder
einen L- oder D-Aminosulfonsäurerest oder die entsprechenden omega-Aminosäuren oder Salze oder
Hydrate derselben und Y OH, H, Alkyl, Aryl, Aralkyl oder eine C-terminale Blockierungsgruppe
bedeuten, mit der Maßgabe, daß A nicht Asp oder Glu sein kann, wenn B Phe und Y Alkyl ist, oder BY
einen Aminoalkoholrest

B1-CHY1-OH

bedeutet, wobei B¹ ein Decarboxyderivat der Aminocarbonsäure, wie bezüglich B definiert, und Y¹ H, Alkyl, Aryl oder Aralkyl ist, dadurch gekennzeichnet, daß man eine Substratkomponente, die ein Aminosäurederivat der Formel

H-A-OR¹ oder H-A-NR²R³

ist, wobei A wie oben definiert ist, sowie R¹ Alkyl, Aryl oder Aralkyl, gegebenenfalls mit inerten Substituenten, oder ein alpha-Desaminofragment einer Aminosäure und R² und R³, die gleich oder verschieden sind, jeweils Wasserstoff, Alkyl, Aryl oder Aralkyl, gegebenenfalls substituiert mit inerten

Substituenten, bedeuten, mit einer nucleophilen Komponente, ausgewählt aus (a) Aminosäuren der Formel

H-B-OH

5

10

15

20

25

30

35

40

45

55

in der B ein wie oben definierter Aminocarbonsäurerest, (b) Aminosäureamiden der Formel

H-B-NR<sup>2</sup>R<sup>3</sup>

in der B ein wie oben definierter Aminocarbonsäurerest ist und R<sup>2</sup> und R<sup>3</sup> wie oben definiert sind, mit der Ausnahme, daß wenn R<sup>2</sup> Wasserstoff ist, R<sup>3</sup> auch Hydroxy oder Amino sein kann, (c) Aminosäureestern der Formel

H-B-OR4

in der B ein wie oben definierter Aminocarbonsäurerest ist und R<sup>4</sup> Alkyl, Aryl oder Aralkyl bedeutet, (d) gegebenenfalls säuregruppengeschützten, geradkettigen oder verzweigten Aminophosphonsäuren oder Aminosulfonsäuren der Formel

 $NH^2(CH_2)_xPO_3R^5R^6$  oder  $NH_2(CH_2)_xSO_3R^7$ 

in der  $R^5$ ,  $R^6$  und  $R^7$  unabhängig voneinander Wasserstoff, Alkyl, Aryl oder Aralkyl und x 1 - 6 bedeuten.

(e) Aminosäurealdehyden oder Ketonen oder Derivaten derselben der Formel

H-B1-CY2-R8

in der B¹ wie oben definiert, Y² O oder ein funktionelles Derivat desselben, vorzugsweise ein Ketal und R³ H, Alkyl, Aryl oder Aralkyl bedeuten, und (f) Aminoalkoholen der Formel

H-B1-CHY1-OH

.... 0.... 0

in der B¹ und Y¹ wie oben definiert sind, in Gegenwart eines Amidase- oder Esteraseenzyms, das von Serin- oder Thiolcarboxypeptidasen verschieden ist, in Lösung oder Dispersion umsetzt und anschließend, falls erwünscht, eine vorhandene Seitenkettenschutzgruppe oder Schutzgruppe Y abspaltet und/oder, falls erwünscht, das

erhaltene Dipeptidderivat in ein Salz oder Hydrat überführt.

- Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß man ein Enzym mit Esterase- oder Amidase-Aktivität verwendet, das von Serin- oder Thiolendoprotheasen, Lipasen, Esterasen und Glycosidasen ausgewählt ist.
- 3. Verfahren nach Anspruch 1 oder 2, dadurch gekennzeichnet, daß das verwendete Enzym chemisch modifiziert oder ein biosynthetischer Mutant einer natürlichen Form ist.
- 4. Verfahren nach einem jeden der obigen Ansprüche, dadurch gekennzeichnet, daß man ein immobilisiertes Enzym verwendet.
  - 5. Verfahren nach einem jeden der obigen Ansprüche, dadurch gekennzeichnet, daß man eine wässrige Reaktionslösung oder -dispersion verwendet, die 0 90 %, vorzugsweise 0 60 %, eines polaren, wassermischbaren organischen Lösemittels enthält und einen pH-Wert von 3 11, vorzugsweise 5 10,5, besonders bevorzugt 6 10 und insbesondere 7 9,5, aufweist.
  - Verfahren nach Anspruch 5, dadurch gekennzeichnet, daß das organische Lösemittel aus Alkanolen, Dimethylsulfoxid, Dimethylformamid, Dimethoxyethan und Ethylenglykol ausgewählt ist.

- 7. Verfahren nach einem jeden der Ansprüche 1 4, dadurch gekennzeichnet, daß man eine organische Reaktionslösung oder -dispersion verwendet, die 0 10 % Wasser enthält.
- Verfahren nach Anspruch 7, dadurch gekennzeichnet, daß man ein unpolares organisches Lösemittel verwendet, vorzugsweise ausgewählt aus Dialkylethern, Ethylacetat, Ethylpropionat, Octanen, Heptanen, Hexanen, Petrolethern und Methylenchlorid.
  - 9. Verfahren nach Anspruch 7, dadurch gekennzeichnet, daß man ein flüssiges Substrat oder eine nucleophile Komponente verwendet, die ebenfalls als organisches Lösemittel dienen kann.
  - 10. Verfahren nach einem jeden der obigen Ansprüche, dadurch gekennzeichnet, daß man als Substrat-komponente einen D- oder L-Aminosäureester verwendet, der aus Benzylestern oder geradkettigen oder verzweigten C<sub>1</sub>-C<sub>8</sub>-Alkylestern, gegebenenfalls mit inerten Substituenten substituiert, ausgewählt ist.
  - 11. Verfahren einem jeden der obigen Ansprüche, dadurch gekennzeichnet, daß man als nucleophile Komponente ein Aminosäureamid der Formel

H-B-NHR3

20

10

15

- verwendet, in der  $R^3$  Wasserstoff oder  $C_1$ - $C_3$ -Alkyl und B einen L- oder D-Aminocarbonsäurerest bedeuten.
- 12. Verfahren nach einem jeden der Ansprüche 1 bis 10, dadurch gekennzeichnet, daß man als nucleophile Komponente einen Ester der Formel

H-B-OR4

verwendet, in der B ein L- oder D-Aminocarbonsäurerest und R<sup>4</sup> C<sub>1</sub>-C<sub>3</sub>-Alkyl bedeutet.

30

35

40

55

- 13. Verfahren nach einem jeden der obigen Ansprüche, dadurch gekennzeichnet, daß das erhaltene Dipeptid eine C-terminale Schutzgruppe Y oder mehrere einschließt und daß die Gruppe bzw. Gruppen enzymatisch abgespalten wird/werden, und zwar entweder mittels des gleichen Enzyms, das in der vorherigen Reaktion verwendet wurde, oder mittels eines Enzyms, das eine unterschiedliche Esteroder Amidspezifität aufweist.
- 14. Verfahren nach einem jeden der obigen Ansprüche, dadurch gekennzeichnet, daß das erhaltene Dipeptid eine Seitenkettenschutzgruppe oder mehrere einschließt und daß die Gruppe bzw. Gruppen enzymatisch abgespalten wird/werden, vorzugsweise mittels einer Esterase oder Lipase oder eines proteolytischen Enzyms.

### Revendications

1. Procédé de préparation de dipeptides ou de composés ayant une structure apparentée, ayant la formule générale

H-A-B-Y

où A représente un résidu de L- ou D-α-amino-acide ou un résidu de ω-amino-acide, éventuellement protégé sur la chaîne latérale, et B représente un résidu d'acide L- ou D-α-aminocarboxylique, éventuellement protégé sur la chaîne latérale, qui peut être le même que pour A ou différent de celuici, un résidu d'acide L- ou D-aminophosphonique ou un résidu d'acide L- ou D-aminosulfonique ou les ω-amino-acides correspondants ou les sels et hydrates de ceux-ci, et Y représente OH, H, alkyle, aryle, aralkyle ou un groupe bloquant C-terminal, à la condition que A ne puisse pas être Asp ou Gly quand B est Phe et quand Y est un groupe alkyle, ou BY représente un résidu d'amino-alcool

B1-CHY1-OH

où B¹ est un dérivé décarboxy des acides aminocarboxyliques tels qu'ils sont définis en relation avec B, et Y¹ représente H ou un groupe alkyle, aryle ou aralkyle,

caractérisé en ce qu'on fait réagir un composant de substrat qui est un dérivé d'amino-acide ayant la formule

 $H-A-OR^1$  ou H-A-N

10

15

5

où A est défini comme ci-dessus, R¹ représente un groupe alkyle, aryle ou aralkyle éventuellement substitué par des substituants inertes ou un fragment α-désamino d'un amino-acide, et R² et R³ sont identiques ou différents l'un de l'autre et représentent un atome d'hydrogène ou un groupe alkyle, aryle ou aralkyle éventuellement substitué par des substituants inertes, avec un composant nucléophile choisi parmi

(a) des amino-acides ayant la formule

н-в-он

20

- où B est un résidu d'acide aminocarboxylique tel qu'il est défini ci-dessus,
- (b) des amides d'amino-acides ayant la formule

25

30

35

40

45

$$H-B-N$$
 $R^2$ 

où B est un résidu d'acide aminocarboxylique tel qu'il est défini ci-dessus, et  $R^2$  et  $R^3$  ont la signification indiquée ci-dessus, sauf que  $R^3$  peut aussi représenter un groupe hydroxy ou amino quand  $R^2$  représente un atome d'hydrogène,

(c) des esters d'amino-acides ayant la formule

H-B-OR

où a est un résidu d'acide aminocarboxylique tel qu'il est défini ci-dessus, et R<sup>4</sup> représente un groupe alkyle, aryle ou aralkyle,

(d) des acides aminophosphoniques ou des acides aminosulfoniques à chaîne droite ou ramifiée, éventuellement protégés par un groupe d'acide, ayant la formule

NH2(CH2)xPO3R5R6 ou NH2(CH2)xSO3R7

où R<sup>5</sup>, R<sup>6</sup> et R<sup>7</sup> représentent, indépendamment les uns des autres, un atome d'hydrogène ou un groupe alkyle, aryle ou aralkyle, et x vaut de 1 à 6,

(e) des aldéhydes ou des cétones d'amino-acides ou leurs dérivés, ayant la formule

H-B1-CY2-R8

où B¹est déf

où B¹ est défini comme ci-dessus, Y² représente O ou un dérivé fonctionnel de celui-ci, de préférence un cétal, et R8 représente H ou un groupe alkyle, aryle ou aralkyle, et (f) des amino-alcools ayant la formule

H-B1-CY1-OH

55

où B¹ et Y¹ ont la signification indiquée ci-dessus, en présence d une enzyme amidase ou estérase différente de la sérine ou de la thiolcarboxypeptidase, en solution ou en dispersion, et ensuite, si on le désire, on sépare par clivage un groupe

protecteur présent de la chaîne latérale ou un groupe protecteur Y et/ou, si on le désire, on transforme le dérivé dipeptide résultant en un sel ou un hydrate.

- Procédé selon la revendication 1, caractérisé en ce qu'on utilise une enzyme ayant une activité d'estérase ou d'amidase, qu'on choisit parmi la sérine ou des thiolendoprotéases, des lipases, des estérases et des glycosidases.
  - 3. Procédé selon la revendication 1 ou 2, caractérisé en ce que l'enzyme utilisée a été modifiée chimiquement ou est un mutant biosynthétique d'une forme naturelle.
  - 4. Procédé selon l'une quelconque des revendications précédentes, caractérisé en ce qu'on utilise une enzyme immobilisée.
- 5. Procédé selon l'une quelconque des revendications précédentes, caractérisé en ce qu'on utilise une solution ou une dispersion aqueuse de réaction contenant de 0 à 90%, de préférence de 0 à 60 %, d'un solvant organique polaire miscible avec l'eau et ayant un pH de 3 à 11, de préférence de 5 à 10,5, et de manière plus préférée de 6 à 10, en particulier de 7 à 9,5.
- 6. Procédé selon la revendication 5, caractérisé en ce qu'on choisit le solvant organique parmi des alcanols, le diméthylsulfoxyde, le diméthylformamide, le diméthoxyéthane et l'éthylèneglycol.
  - 7. Procédé selon l'une quelconque des revendications 1 à 4, caractérisé en ce qu'on utilise une solution ou une dispersion organique de réaction contenant de 0 à 10 % d'eau.
- Procédé selon la revendication 7, caractérisé en ce qu'on utilise un solvant organique non polaire, qu'on choisit, de préférence, parmi des éthers dialkyliques, l'acétate d'éthyle, le propionate d'éthyle, des octanes, des heptanes, des hexanes, l'éther de pétrole et le chlorure de méthylène.
- Procédé selon la revendication 7, caractérisé en ce qu'on utilise un substrat liquide ou un composant
   nucléophile qui peut aussi servir de solvant organique.
  - 10. Procédé selon l'une quelconque des revendications précédentes, caractérisé en ce qu'on utilise, comme composant de substrat, un ester de D- ou L-amino-acide, choisi parmi les esters benzyliques ou les esters d'alkyle en C<sub>1</sub>-C<sub>8</sub> à chaîne droite ou ramifiée, éventuellement substitués par des substituants inertes.
  - Procédé selon l'une quelconque des revendications précédentes, caractérisé en ce qu'on utilise, comme composant nucléophile, un amide d'amino-acide ayant la formule

### 40 H-B-NHR3

35

55

10

- où  $R^3$  est un atome d'hydrogène ou un groupe alkyle en  $C_1$ - $C_3$ , et B est un résidu d'acide L- ou D-aminocarboxylique.
- 45 12. Procédé selon l'une quelconque des revendications 1 à 10, caractérisé en ce qu'on utilise, comme composant nucléophile, un ester ayant la formule

### H-B-OR⁴

- où B est un résidu d'acide L- ou D-aminocarboxylique, et R<sup>4</sup> est un groupe alkyle en C<sub>1</sub>-C<sub>3</sub>.
  - 13. Procédé selon l'une quelconque des revendications précédentes, caractérisé en ce que le dipeptide résultant comprend un ou plusieurs groupes protecteurs Y C-terminaux, et que ce groupe ou ces groupes sont séparés enzymatiquement au moyen de la même enzyme que celle utilisée lors de la réaction précédente ou au moyen d'une enzyme ayant une spécificité différente d'ester ou d'amide.
  - 14. Procédé selon l'une quelconque des revendications précédentes, caractérisé en ce que le dipeptide résultant comprend un ou plusieurs groupes protecteurs de la chaîne latérale et que ce groupe ou ces

groupes sont séparés enzymatiquement, de préférence au moyen d'une estérase ou d'une lipase ou d'une enzyme protéolytique.